T-Cell Immunotherapy Market, 2015-2030

1. T-Cell Immunotherapy Market, 2015-2030 Roots Analysis https://www.rootsanalysis.com/reports/view_document/t-cell-immunotherapy-market-2015-2030/108.html https://www.rootsanalysis.com/

2. Overview WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades. In the US alone, over one million people are diagnosed with cancer each year. Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. Specifically, immuno-oncology has been gradually nurtured by researchers over the last several years. Post an evident shift towards the development of therapeutics targeting cancer cells by harnessing immune system components, immunotherapeutics have gained a strong foothold in the pharmaceutical industry. After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market. Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. T-cell immunotherapy is structured into segments comprising of CAR-T, TCR and TIL therapies. Academicians across the globe have significantly contributed by convening the initial research of the candidates; this has served as the framework for several start-ups / established industry players to drive the research forward.

3. Scope of the Report The “T-Cell Immunotherapy Market, 2015-2030” report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies. The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children’s Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children’s Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system. The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia. One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas:

4. The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications • Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation • Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen • Various investments and grants received by the companies focused in this area • Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas • Competitive landscape, challenges and expected trend of market evolution within the three sub-segments • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

5. Contents Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term. Chapter 3 provides a general introduction to T-cell immunotherapy. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and the reasons supporting the gradual emergence of T-cell therapies. Chapter 4 provides a comprehensive landscape of the T-cell immunotherapy market. It includes information on therapies which are currently in different stages of development (both clinical and preclinical/discovery). The detailed analysis of this pipeline includes information on most commonly targeted indications, current phases of development, the targets and the type of developers for each of the therapies.

6. Contact: Gaurav Chaudhary +1 (415) 800 3415 +44 (122) 391 1091 Gaurav.Chaudhary@rootsanalysis.com https://www.rootsanalysis.com/reports https://www.rootsanalysis.com/press-releases.html